Aimmune’s Palforzia Gains US FDA Panel Nod But Faces REMS Restrictions

The agency’s plan to require a Risk Evaluation and Mitigation Strategy aimed at systemic allergic reactions with the peanut allergy immunotherapy did not go far enough, advisory committee members said, pushing for additional measures to be folded into the program.